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Background: Cerebrospinal fluid (CSF) biomarkers’ performance for predicting conversion
from mild cognitive impairment (MCI) to Alzheimer’s disease (AD) is still suboptimal.
Objective: By considering several confounding factors we aimed to identify in which
situations these CSF biomarkers can be useful.
Data Sources: A systematic review was conducted on MEDLINE, PreMedline, EMBASE,
PsycInfo, CINAHL, Cochrane, and CRD (1990–2013).
Eligibility Criteria: (1) Prospective studies of CSF biomarkers’ performance for predicting
conversion from MCI to AD/dementia; (2) inclusion of Aβ42 and T-tau and/or p-tau. Several
meta-analyses were performed.
Results: Aβ42/p-tau ratio had high capacity to predict conversion to AD in MCI patients
younger than 70 years.The p-tau had high capacity to identify MCI cases converting to AD
in ≤24 months.
Conclusions: Explaining how different confounding factors influence CSF biomarkers’ pre-
dictive performance is mandatory to elaborate a definitive map of situations, where these
CSF biomarkers are useful both in clinics and research.
Keywords: mild cognitive impairment, Alzheimer’s disease, CSF biomarkers, confounding factors, meta-analysis,
systematic review
INTRODUCTION
Mild cognitive impairment (MCI) is a high risk factor for develop-
ing dementia, particularly Alzheimer’s disease (AD). About 35%
of MCI patients progress to AD, with an annual conversion rate of
5–10% (Mitchell, 2009). Because AD entails severe consequences,
an appropriate prediction of MCI outcome is crucial for giving the
patients a prognosis and to initiate therapeutical strategies as soon
as possible. In this regard, the new MCI diagnostic criteria rec-
ommended by the National Institute of Aging – Alzheimer’s Asso-
ciation (NIA-AA) emphasize the use of neuroimaging and cere-
brospinal fluid (CSF) biomarkers (Albert et al., 2011). Although
significant advances have been made in the field of neuroimaging,
biomarkers based on CSF are at present the most convenient for
studying disease progression.
The currently validated CSF biomarkers of AD are Aβ42, total
tau (T-tau), and phosphorylated tau (p-tau). CSF Aβ42 is reduced,
and T-tau and p-tau levels are increased in MCI patients compared
to healthy controls (Diniz et al., 2008). In addition, MCI patients
with abnormal CSF biomarkers have increased risk to progress
to AD (Herukka et al., 2005; Hansson et al., 2006, 2007; Bouw-
man et al., 2007; Brys et al., 2009; Mattsson et al., 2009; Shaw
et al., 2009; Hertze et al., 2010; Buchhave et al., 2012). Buchhave
et al. (2012) showed that 90% of MCI patients with pathologic
CSF biomarkers developed AD within 9·2 years. This knowledge is
now incorporated in the new diagnostic criteria for MCI, indi-
cating that positive biomarkers of Aβ accumulation (e.g., CSF
Aβ42) and neuronal injury (e.g., CSF T-tau and p-tau) confers
the highest likelihood that AD pathophysiological processes are
the cause of the cognitive dysfunction; and that individuals with
this biomarker profile are more likely to decline or progress to
dementia due to AD in relatively short periods (Albert et al., 2011).
Regarding predictive capacity, although single CSF biomarkers
have shown unsatisfactory results, their combination could be
suitable to identify which MCI patients will progress to dementia
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(Ferreira et al., 2014). In particular, the Aβ42/p-tau ratio has
demonstrated high efficiency (Hansson et al., 2006; Mattsson et al.,
2009; Buchhave et al., 2012; Parnetti et al., 2012; Roe et al., 2013).
Two systematic reviews with meta-analysis have previously been
published (Mitchell, 2009; Monge-Argilés et al., 2010). Mitchell
(2009) only evaluated p-tau. Monge-Argilés et al. (2010) evalu-
ated the three CSF biomarkers, but the group of MCI patients
that converted to AD was compared to a mixed group of stable
MCI cases and MCI patients that converted to non-AD demen-
tias. Moreover, their analysis of combined CSF biomarkers was
limited to only three studies and the combination procedure was
not sufficiently detailed.
Importantly, CSF biomarkers’ predictive performance could
be improved by considering different confounding factors such
as the MCI subtype, time to AD conversion, and age (Ferreira
et al., 2014). Previous studies show that the CSF biomarkers have
better predictive capacity in amnestic MCI (Vos et al., 2013),
MCI patients that convert to AD in relatively short periods (e.g.,
<12 months) (Gaser et al., 2013), and young MCI patients (Matts-
son et al., 2012). However, most of the studies performed to date
do not consider these confounding factors. These aspects together
with methodological variability have made it difficult to propose
definitive cut-off values for CSF biomarkers. For this reason, the
fact of disseminating the use of CSF biomarkers to clinical routine
is compromised at present (Ferreira et al., 2014).
The main objective in this study was to carefully evaluate the
capacity of the CSF biomarkers to predict conversion from MCI to
AD in several clinically relevant situations. In particular, we aimed
to identify for which specific MCI patients these CSF biomark-
ers might be useful in clinical practice. In order to address this
question, several meta-analyses were performed for studies that
prospectively analyzed the predictive performance of CSF Aβ42
and T-tau and/or p-tau. The design of the included studies is
baseline cross-sectional comparisons between MCI patients that
convert to AD or dementia (MCI-C) and MCI patients that remain
stable (MCI-S) at follow-up. We hypothesized that combined CSF
biomarkers would have better predictive performance than sin-
gle CSF biomarkers, and that this performance could be increased
by controlling for different confounding factors such as the MCI
subtype, time to AD conversion, and age, among others.
MATERIAL AND METHODS
SEARCH STRATEGY AND SELECTION CRITERIA
A systematic review was conducted for the period between Jan-
uary 1990 and September 2013 in the following electronic data-
bases: MEDLINE and PreMedline, EMBASE, PsycInfo, CINAHL,
Cochrane Library, and CRD. The search strategy was developed
for each database using the following Medical Subject Heading
(MeSH) and free-text terms: “Alzheimer’s disease diagnosis” or
“Alzheimer’s disease,” and “abeta-42” or “T-tau” or “P-tau” or “tau”
or “phospho-tau” or “phosphorylated tau.” Examples for the two
major databases are shown in Table S1 in Supplementary Materials
(MEDLINE) and Table S2 in Supplementary Materials (EMBASE).
In addition, reference sections were searched to identify relevant
publications.
Inclusion criteria for this meta-analysis were studies that
(1) performed a prospective analysis of the CSF biomarkers’
Records screened by 
title and abstracts 
(n = 158)
12 articles included 
(10 studies)
duplicates were removed 
(n = 1308)
database search in Sep 2013 
(n = 1587)
Duplicates (n = 279) 
Records excluded by 
title / abstract 
(n = 1150)
Articles excluded 
and reasons 
(n= 146) 
-Design: 78
-Intervention: 25 
-Outcomes: 31 
-Participants: 10
-Language: 2
FIGURE 1 | Study selection flow.
performance for predicting conversion to AD or dementia in
individuals with MCI at baseline; (2) included at least two CSF
biomarkers, being Aβ42 always required along with T-tau and/or
p-tau; and (3) were published in English or Spanish. Studies were
excluded if they did not report sensitivity or specificity values, or
any other data that enabled its calculation. Two reviewers indepen-
dently performed the study selection (Daniel Ferreira and Amado
Rivero-Santana),and in case of doubt and/or disagreements a third
reviewer was consulted (Lilisbeth Perestelo-Pérez). The search
yielded 1308 references after discarding duplicates. One-hundred
fifty-eight articles were selected by title and abstract. After apply-
ing eligibility criteria, 12 articles were eventually included (Hampel
et al., 2004; Herukka et al., 2005; Parnetti et al., 2006, 2012; Ecker-
ström et al., 2010; Hertze et al., 2010; Monge-Argilés et al., 2011;
Buchhave et al., 2012; Ewers et al., 2012; Gaser et al., 2013; Toledo
et al., 2013; Vos et al., 2013). Three of these studies included data
from the Alzheimer’s Disease Neuroimaging Initiative (ADNI).
As these studies represent different analyses of overlapping ADNI
subsamples, only one ADNI study was included for each meta-
analysis depending on the analyzed biomarker. If two ADNI stud-
ies were available for the same biomarker, the one with largest
sample was selected. Selection flow including reasons for study
exclusion at each phase is shown in Figure 1.
DATA COLLECTION, RISK OF BIAS, AND EVALUATION OF
METHODOLOGICAL QUALITY
A data extraction sheet was developed to collect relevant data
by covering: author and publication year, country, objectives,
methods (with special attention to participants’ recruitment pro-
cedures, study design, follow-up length, CSF biomarkers evaluated
including Aβ42/T-tau and Aβ42/p-tau ratios, diagnostic groups
characteristics, and statistical analyses), results, and conclusions.
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Data extraction was carried out by two researchers (Daniel Fer-
reira and Amado Rivero-Santana), and quality and accuracy
of the extraction was verified by a third researcher (Lilisbeth
Perestelo-Pérez).
Several strategies were followed in order to reduce the risk of
bias related to publication, data availability, and reviewer selec-
tion (see Table S3 in Supplementary Materials). The QUADAS-
2 scale (Whiting et al., 2011) was used in order to assess the
methodological quality of the included studies. The scale was
applied by two researchers (Amado Rivero-Santana and Daniel
Ferreira), and in case of doubt and/or disagreements a third
was consulted (Lilisbeth Perestelo-Pérez). Finally, this study was
performed in accordance with the PRISMA statement (Liberati
et al., 2009; Moher et al., 2010), which provides a detailed
guideline of preferred reporting style for systematic reviews and
meta-analyses.
IDENTIFICATION OF POTENTIAL CONFOUNDING FACTORS OF CSF
BIOMARKERS’ PREDICTIVE PERFORMANCE
We hypothesized that CSF biomarkers’ predictive performance
might be influenced by different confounding factors. To explore
sources of heterogeneity, the following factors were defined a priori
based on the literature (see Table 1 for a detailed description of the
different factors and considered categories): (1) recruitment set-
ting; (2) MCI subtype; (3) diagnostic criteria for MCI at baseline;
(4) diagnostic criteria for AD at follow-up; (5) postmortem confir-
mation of AD pathology; (6) criteria for conversion from MCI to
AD/dementia; (7) diagnosis at follow-up; (8) follow-up length (as
rough estimation of time to AD conversion); (9–11) MCI severity
at baseline according to mini-mental state examination (MMSE),
clinical rating [e.g., clinical dementia rating (CDR), global dete-
rioration scale (GDS)], and magnetic resonance imaging (MRI)
rating (i.e., degree of brain atrophy); (12) Age; (13) gender distri-
bution; (14) years of education; (15) family history of AD; (16)
APOE e4 status; (17) technology applied for the CSF analysis; and
(18) cut-offs for interpreting the CSF levels.
STATISTICAL ANALYSIS
For each article, true and false positives/negatives values were
calculated from sensitivity, specificity, positive predicted value,
negative predicted value, and/or the rate of converters and non-
converters. A global meta-analysis was performed for each single
CSF biomarker (i.e., Aβ42, T-tau, and p-tau) and two relevant
ratios (i.e., Aβ42/T-tau and Aβ42/p-tau). Analyses were performed
with the MetaDisc 1.1.1 software (Zamora et al., 2006). Sen-
sitivity and specificity pooled estimates were calculated with
random-effects models (DerSimonian and Laird, 1986), which
yield more conservative estimates. For a qualitative interpretation
of sensitivity and specificity results, values above 80% were consid-
ered indicative of satisfactory predictive performance according to
international recommendations (The Ronald and Nancy Reagan
Research Institute of the Alzheimer’s Association and the national
Institute on Aging working Group, 1998). Positive and negative
likelihood ratios were calculated from resulting sensitivity and
specificity values and interpreted following established guidelines
(see these guidelines in Figure 2 footnotes) (Qizilbash, 2002). Like-
lihood ratios indicate how the pretest probability of disease is
increased or decreased by the outcome of a diagnostic test. A pos-
itive likelihood ratio [LR+= sensitivity/(1 – specificity)] greater
than one increases the probability that the disease is present (in
this context progression to AD) and helps to rule-in MCI-C cases.
A negative likelihood ratio (LR–= (1 – sensitivity)/specificity) of
less than one diminishes the probability that disease is present
and helps to rule-out MCI-C cases. Statistical heterogeneity was
explored with the Cochran Q-test. As this statistic has low power
when few studies are available, a recommended p-value of 0·10 was
established as statistical significance threshold to detect hetero-
geneity (Hardy and Thompson, 1998). Differences in sensitivity
and specificity values for pairs of subgroup meta-analyses (e.g.,
MCI cases younger than 70 years vs. older than 70 years) were
tested with the formula: QBET=QTOT – (Q1+Q2). Where QTOT
represents the overall inter-study variability, andQ1 andQ2 repre-
sents inter-study variability for each subgroup in the comparison
(Deeks et al., 2001). The QBET statistic was then compared to a
χ2 distribution with J− 1 degrees of freedom using a significance
level of 0·05, where J is the number of subgroups.
RESULTS
MAIN CHARACTERISTICS OF INCLUDED STUDIES AND
METHODOLOGICAL QUALITY
Among the 12 studies included, 10 offered data about the diag-
nostic performance of Aβ42, 6 about T-tau, 5 about p-tau, and 6
about the Aβ42/T-tau and Aβ42/p-tau ratios. Main study character-
istics are detailed in Table 2. Methodological quality (QUADAS-2)
is shown in Table S4 in Supplementary Materials. In summary,
(1) Patient selection: only two studies demonstrated low risk of
bias; seven did not explicitly state consecutive or random sam-
ples; patients could have been inappropriately excluded in nine
studies. (2) Diagnostic test: seven studies proved low risk of bias
by using external cut-off values or establishing the cut-off in the
study sample independently of the clinical diagnosis [i.e., mixture
model analysis in Buchhave et al., 2012]. (3) Diagnostic criterion:
all the studies were classified as unclear given that postmortem
confirmation of AD pathology was never performed. (4) Patients
flow and follow-up: three studies demonstrated low risk of bias; all
the studies applied the same reference standard to all the patients,
but patients were followed during only two years or less in five
studies; six studies did not include all baseline patients in the final
analyses.
GLOBAL META-ANALYSIS: CSF BIOMARKERS’ PREDICTIVE
PERFORMANCE
Table 3 shows sensitivity and specificity values with 95% CI, het-
erogeneity, and likelihood ratios. Heterogeneity was significant
for the three single biomarkers as well as for the two evaluated
ratios. Aβ42/p-tau ratio showed the best performance with 85%
sensitivity, 79% specificity, and a negative likelihood ratio of 0·19,
indicating moderate decrease in the probability that the disease is
present.
SUBGROUPS META-ANALYSES: IDENTIFICATION OF CLINICAL
SITUATIONS WITH INCREASED CSF BIOMARKERS’ PREDICTIVE
PERFORMANCE
Table 1 shows the list of potential confounding factors defined
a priori based on the literature. Due to the low variability across the
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Table 1 | Potential confounding factors of CSF biomarkers’ predictive performance.
Factors Considered categories
RECRUITMENT
Setting Specialized centers (9+1) vs. primary care (0) vs. general population (0)
DIAGNOSTIC ISSUES
MCI subtype Amnestic MCI (6+1) vs. non-amnestic MCI (1) vs. mixed sample (2)a vs. non-specified (1)
Diagnostic criteria for MCI at baseline Petersen et al. (1999, 2001); Petersen, 2004 or Petersen’s group 2006b (8) vs. Winblad et al. (2004) (1) vs.
ADNI criteria (+1)
Diagnostic criteria for AD at follow-up NINCDS-ADRDA (8+1) vs. non-specified (1)
Postmortem confirmation of AD pathology All the studies lacked postmortem confirmation of AD pathology (0)
Diagnosis at follow-up AD (6+1) vs. mixed group of dementias (3)c
Criteria for conversion Fulfillment of diagnostic criteria (7+1) vs. Decline in clinical scales (e.g., CDR) (1) vs. non-specified (1)
TIMETO AD CONVERSION
Time to AD conversion Follow-up ≤24 months (5+1) vs. Follow-up >24 months (4)
MCI SEVERITY AT BASELINE
MMSE total score No enough variability: all studies reporting MMSE have mean scores between 23 and 30 (7+1) vs.
non-specified (2)
Clinical rating CDR=0.5/GDS=3 (5+1) vs. Non-specified (4)
MRI rating Only available for 2 (+1) studies, with variability in procedures
DEMOGRAPHICS/RISK FACTORS AT BASELINE
Age ≤70 years (4) vs. >70 years (4+1) vs. non-specified (1)
Gender Results are never presented separately for men and women (0)
Education ≤12 years (3) vs. >12 years (+1) vs. non-specified (6)
Family history of AD Not enough information (1)
APOE e4 status Not enough information (3+1)
CSF METHODS
Technology for CSF analysis ELISA (6) vs. xMAP (3+1)
Cut-offs for interpreting CSF levels Great variability: Internal (highest value of SN+SP or Youden’s Index) (3) vs. External or independent of
clinical diagnosis (Mixture model analysis, obtained from another cohort in the same study; Hulstaert et al.,
1999; Sjögren et al., 2001; Shaw et al., 2009; Zetterberg et al., 2003) (4+1) vs. both internal and external (2)
Between brackets, number of studies available for at least one biomarker;+1 refers to ADNI studies (only one ADNI study is included for each subgroup meta-analysis).
aHerukka et al. (2005) included amnestic MCI patients as well as patients with other types of cognitive decline. Monge-Argilés et al. (2011) included a mixed group
of amnestic MCI and non-amnestic MCI patients.
bDiagnostic criteria for MCI published by Petersen’s group in Artero et al. (2006).
cBoth in Parnetti et al. (2006) and Monge-Argilés et al. (2011) it is unclear whether MCI converters progressed exclusively to AD.
MCI, mild cognitive impairment; AD, Alzheimer’s disease; MMSE, mini-mental state examination; MRI, magnetic resonance imaging; APOE, apolipoprotein E; CSF,
cerebrospinal fluid; ADNI: Alzheimer’s disease neuroimaging initiative; NINCDS-ADRDA, National Institute of Neurological and Communicative Disorders and Stroke
and the Alzheimer’s Disease and Related Disorders Association; CDR, clinical dementia rating; GDS, global deterioration scale.
studies, it was only possible to perform subgroups meta-analyses
for the following factors: (1) MCI subtype (studies exclusively
including amnestic MCI cases); (2) diagnosis at follow-up (stud-
ies including MCI patients that converted exclusively to AD); (3)
follow-up length (as rough estimation of time to AD conver-
sion: ≤24 months vs.> 24 months); (4) age (studies with mean
age younger vs. older than 70 years); and (5) technology for CSF
analysis (ELISA vs. xMAP). As controlled factors, all the studies
included samples from specialized centers; lacked postmortem
AD confirmation; used comparable diagnostic criteria for MCI;
applied NINCDS-ADRDA criteria for AD diagnosis [except one
study (Herukka et al., 2005)]; and included MCI cases with sim-
ilar global cognitive status (i.e., MMSE). Information on MCI
severity according to MRI rating, gender distribution, level of edu-
cation, family history of AD, and APOE e4 status was scarce or
absent.
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FIGURE 2 | Positive and negative likelihood ratios. A LR+ greater than
one increases the pretest probability that the disease is present [in this
context progression from MCI to AD or, in other words, MCI due to AD
(Albert et al., 2011)]. A LR– of less than one diminishes the pretest
probability that disease is present. The established guidelines (Qizilbash,
2002) states that a LR+ greater than 10 will often make conclusive
changes to the pretest probability, indicating that the disease is likely
present; a LR+ between 5 and 10 corresponds to moderate increase in
probability; and a LR+ between 2 and 5 corresponds to small increase. A
LR− of less than 0·1 will often make conclusive changes to the pretest
probability that the disease is present, indicating that the disease is
unlikely present; a LR− between 0·1 and 0·2 corresponds to moderate
decrease in probability; and a LR− between 0·2 and 0·5 corresponds to
small decrease. LR+, positive likelihood ratio; LR−, negative likelihood
ratio; Global MA, global meta-analysis; MCI, mild cognitive impairment;
AD, Alzheimer’s disease.
Table 3 shows sensitivity and specificity values with 95%
CI, inter-groups difference (QBET), heterogeneity, and likelihood
ratios. Heterogeneity was significant in most of the subgroups
meta-analyses. Noteworthy, CSF biomarkers’ predictive perfor-
mance was optimal (>80%) in two clinically relevant situations,
and heterogeneity was no longer significant: (1) P-tau alone had
84% sensitivity and 93% specificity for MCI cases converting to
AD in ≤24 months, significantly different from 59% sensitivity
(p= 0·01) and 71% specificity (p< 0·001) in studies with follow-
up periods> 24 months; (2) Aβ42/p-tau ratio showed 81% sensi-
tivity and 91% specificity in MCI patients younger than 70 years,
significantly different from 66% specificity in MCI patients older
than 70 years (p< 0·001).
Aβ42/p-tau ratio showed the best performance across the dif-
ferent subgroups meta-analyses. Sensitivity was slightly increased
in studies including only amnestic MCI cases (heterogeneity no
longer significant), MCI patients older than 70 years (heterogene-
ity no longer significant), and studies using ELISA. Aβ42/T-tau
ratio yielded optimal sensitivity values, but suboptimal specificity.
Results were not satisfactory for single CSF biomarkers, except for
the remarkably good p-tau diagnostic performance commented
above.
The analysis of positive likelihood ratios showed extremely high
increase in the probability that the disease is present (LR+= 12)
for p-tau in MCI cases converting to AD in≤24 months (Figure 2;
Table 3). Moreover, there was a moderate increase in the proba-
bility that the disease is present (LR+= 5–10) for the Aβ42/p-tau
ratio in two situations: MCI patients younger than 70 years; and
studies using ELISA technology. The analysis of negative likeli-
hood ratios showed moderate decrease in the probability that the
disease is present (LR–= 0.1–0.2) in several situations: p-tau and
Aβ42/T-tau ratio in MCI cases converting to AD in ≤24 months;
Aβ42/p-tau ratio in the global meta-analysis as well as in all the
subgroups meta-analyses (except in MCI patients younger than
70 years and studies using ELISA technology).
DISCUSSION
The two main findings in this study are that the Aβ42/p-tau
ratio has high capacity to predict AD conversion in MCI patients
younger than 70 years; and p-tau alone has high capacity to iden-
tify MCI cases converting to AD in ≤24 months. The analysis of
likelihood ratios showed that, in both situations, a CSF test result
indicating pathological values of Aβ42/p-tau or p-tau significantly
increase the probability that the disease is present [in this context
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Table 3 | Global meta-analysis and subgroups meta-analyses.
Biomarker Meta-analysis Sensitivity
(%)
Q Inter-groups
difference (QBET)
Specificity
(%)
Q Inter-groups
difference (QBET)
LR+ LR−
Aβ42 Global (n=10)a 79 (75–83) 47.88*** – 72 (68–75) 60.19*** – 2.82 0.29
Amnestic MCI (n=7) 81 (77–86) 33.83*** – 71 (66–75) 59.66*** – 2.79 0.27
AD at follow-up (n=7) 81 (76–85) 32.03*** – 70 (66–74) 51.90*** – 2.70 0.27
Follow-up ≤24 months (n=5)a 73 (65–80) 18.67** 6.76 (p=0.009) 69 (63–75) 15.69** 1.61 (p=0.20) 2.36 0.39
Follow-up>24 months (n=5) 84 (78–88) 22.45*** 74 (69–79) 42.89*** 3.23 0.21
Age≤70 (n=5)a 77 (71–82) 26.20*** 5.77 (p=0.02) 74 (69–79) 31.33*** 7.29 (p=0.007) 2.96 0.31
Age>70 (n=4) 86 (80–91) 5.95 63 (56–70) 13.71** 2.32 0.22
xMAP (n=4) 88 (83–92) 6.04 20.18 (p<0.001) 67 (61–73) 16.41*** 3.30 (p=0.07) 2.67 0.18
ELISA (n=6)a 70 (63–77) 21.66** 74 (69–79) 40.48*** 2.69 0.41
T-tau Global (n=8)a 72 (66–77) 18.62∗ – 70 (66–74) 60.06*** – 2.40 0.40
Amnestic MCI (n=5) 70 (64–77) 12.34∗ – 68 (63–74) 30.68*** – 2.19 0.44
AD at follow-up (n=5)a 72 (66–78) 13.46∗ – 65 (60–70) 18.45** – 2.06 0.43
Follow up≤24 months (n=5)a 73 (65–80) 11.94∗ 0.32 (p=0.57) 75 (69–80) 43.58*** 4.83 (p=0.03) 2.92 0.36
Follow up>4 months (n=3) 70 (61–78) 6.36∗ 65 (59–72) 11.65** 2.00 0.46
Age≤70 (n=3)a 73 (64–80) 4.63 0 (p=1) 69 (63–75) 31.98*** 0.35 (p=0.55) 2.36 0.39
Age>70 (n=4) 73 (65–79) 10.58∗ 67 (60–73) 10.70* 1.97 0.40
xMAP (n=3) 69 (60–77) 4.45 0.97 (p=0.32) 69 (62–75) 6.77* 0.21 (p=0.65) 2.23 0.45
ELISA (n=5)a 74 (66–81) 13.20∗ 71 (65–76) 53.08*** 2.55 0.37
p-tau Global (n=5) 63 (55–71) 21.22*** – 76 (70–80) 51.57*** – 2.63 0.49
Amnestic MCI (n=3) 56 (47–65) 8.66∗ – 80 (74–85) 33.41*** – 2.80 0.55
AD at follow-up (n=3) 59 (51–68) 15.05*** – 71 (65–77) 35.49*** – 2.04 0.58
Follow up≤24 months (n=2) 84 (64–95) 0.07 6.1 (p=0.01) 93 (83–98) 1.92 14.16 (p<0.001) 12.00 0.17
Follow up>24 months (n=3) 59 (51–68) 15.05*** 71 (65–77) 35.49*** 2.03 0.58
Age≤70 – – – – – – – –
Age>70 (n=3) 59 (51–68) 13.79** 81 (75–86) 34.23*** 3.10 0.50
xMAP (n=3) 57 (48–66) 11.01** 10.06 (p=0.001) 78 (72–84) 25.48*** 2.63 (p=0.10) 2.59 0.55
ELISA (n=2) 85 (69–95) 0.15 69 (59–79) 23.46*** 2.74 0.22
Aβ42/T-tau Global (n=5)a 86 (81–90) 21.20*** – 60 (54–65) 42.52*** – 2.15 0.23
Amnestic MCI (n=3) 89 (83–93) 10.62** – 54 (48–61) 22.87*** – 1.94 0.20
AD at follow-up (n=4)a 86 (81–91) 21.20*** – 59 (54–64) 41.15*** – 2.10 0.24
Follow up≤24 months (n=2)a 94 (87–98) 3.86 8.83 (p=0.003) 48 (39–56) 9.00* 13.50 (p<0.001) 1.81 0.13
Follow up>24 months (n=3) 81 (73–87) 8.51∗ 67 (61–73) 20.02*** 2.46 0.28
Age≤70 years (n=2)a 88 (79–93) 18.63*** 0.27 (p=0.6) 56 (48–64) 29.63*** 1.83 (p=0.18) 2.00 0.21
Age>70 years (n=3) 85 (78–91) 2.30 63 (56–70) 11.06** 2.30 0.24
xMAP (n=3) 85 (78–91) 2.30 0.27 (p=0.6) 63 (56–70) 11.06** 1.83 (p=0.18) 2.30 0.24
ELISA (n=2)a 88 (79–93) 18.63*** 56 (48–64) 29.63*** 2.00 0.21
Aβ42/p-tau Global (n=6) 85 (80–89) 12.08* – 79 (74–83) 44.03*** – 4.05 0.19
Amnestic MCI (n=4) 88 (83–92) 2.70 – 78 (72–83) 41.01*** – 4.00 0.15
AD at follow-up (n=5) 85 (80–89) 12.08* – 79 (74–84) 43.77*** – 4.05 0.19
Follow up≤24 months – – – – – – – –
Follow up>24 months (n=5) 85 (80–89) 12.08* 79 (74–84) 43.77*** 4.05 0.19
Age ≤70 years (n=3) 81 (73–88) 7.19* 3.59 (p=0.06) 91 (86–95) 2.07 31.79 (p<0.001) 9.00 0.21
Age>70 years (n=3) 89 (83–94) 1.30 66 (58–74) 10.17** 2.62 0.17
xMAP (n=4) 89 (84–93) 1.47 7.83 (p=0.005) 73 (67–79) 25.23*** 16.76 (p<0.001) 3.30 0.15
ELISA (n=2) 73 (59–84) 2.78† 91 (84–96) 2.04 8.11 0.30
† p<0.10; *p< 0.05; **p<0.01; ***p<0.001.
aNumber of estimations is n+1 due to results were reported separately for amnestic MCI and non-amnestic MCI patients in Vos et al. (2013).
Q, heterogeneity (Cochran Q-test); LR+, positive likelihood ratio; LR−, negative likelihood ratio; Global, global meta-analysis; n, number of studies included in the
meta-analysis; MCI, mild cognitive impairment; AD, Alzheimer’s disease.
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progression from MCI to AD or, in other words, MCI due to AD
(Albert et al., 2011)].
Better predictive performance of the CSF biomarkers in
younger MCI patients has been recently shown in a large multi-
center study (Mattsson et al., 2012). A fact that may explain this
result is that typical AD brain alterations increase with age in indi-
viduals without dementia (Green et al., 2000; Bennett et al., 2006),
with about a third of cognitively normal elderly evidencing an
AD-like pattern of CSF biomarker alterations (Ewers et al., 2007;
Bouwman et al., 2009; Mattsson et al., 2009; Shaw et al., 2009). This
also occurs in stable MCI cases, therefore obstructing specificity
for AD and undermining CSF biomarkers’ performance.
Regarding time to AD conversion, Gaser et al. (2013) showed
that the CSF biomarkers had generally better performance for MCI
cases that converted to AD in<12 months as compared with MCI
cases that converted to AD in >12 months. In the current meta-
analysis, this finding is still valid when considering 24 months
as threshold. However, Buchhave et al. (2012) reported that the
combination of CSF biomarkers might not be recommendable
at 60 months before AD conversion. The reason for this is that
at that point, many MCI-C have normal T-tau levels but already
pathological Aβ42 levels. In another study, the combination of CSF
biomarkers with structural MRI showed >80% sensitivity during
the first 18 months of follow-up, decreasing to 75% at 24 months,
and to 68% at 36 months (Westman et al., 2012). Therefore, pre-
dictive value and biomarkers’ utility strongly depend on the stage
of the disease and time to conversion. Aβ42 performs better than
Tau 5–10 years before conversion to AD, but T-tau and p-tau have
better predictive power 0–5 years before conversion (Buchhave
et al., 2012). Other biomarkers such as those based on structural
MRI have the highest performance the closer to AD diagnosis.
Future research should thus pursue in combining the CSF bio-
markers not only with each other but also with other biomarkers.
Recent studies show an increase in the diagnostic efficiency of CSF
biomarkers when combined with neuroimaging biomarkers (Vos
et al., 2012; Westman et al., 2012; Choo et al., 2013; Galluzzi et al.,
2013; Prestia et al., 2013; Shaffer et al., 2013). The development of
new combinations and indexes may contribute not only to predict
AD conversion but, importantly, to facilitate prediction of time to
conversion, which is still challenging.
Importantly, the Aβ42/p-tau ratio showed satisfactory predic-
tive performance in a heterogeneous group of MCI patients, which
better represents the clinical reality (global meta-analysis). More-
over, it is noteworthy that the sensitivity was increased in two
specific conditions: amnestic MCI patients and old MCI patients
(>70 years). Recently, Vos et al. (2013) showed that the CSF bio-
markers are more sensitive in amnestic MCI than in non-amnestic
MCI patients . An explanation for this is MCI heterogeneity.
Only 30–60% of the MCI patients are affected by prodromal AD,
whereas the others may stem from a variety of different etiologies
and pathologies (Ritchie et al., 2001; Petersen, 2004). The amnes-
tic subtype is mainly associated with AD pathology. Nonetheless,
vascular etiology has also been referred as explicative factor, espe-
cially in those cases with cognitive impairment encompassing
other domains besides memory (Petersen, 2004; Winblad et al.,
2004). On the contrary, the non-amnestic subtype may have higher
likelihood of progressing to non-AD dementias such as dementia
with Lewy bodies or frontotemporal lobar degeneration (Petersen,
2004; Winblad et al., 2004). In this regard, it seems reasonable that
the CSF biomarkers validated for AD perform better in the amnes-
tic MCI cases. In agreement with Vos et al. (2013), this may have
implications for clinical implementation of the new revised cri-
teria for MCI (Albert et al., 2011), given that both amnestic and
non-amnestic subtypes are considered in this criteria as possi-
ble prodromal stages of AD-type dementia. Regarding the finding
of better CSF biomarkers’ sensitivity in old MCI patients, this is
in line with the discussion above about the age-related increase
in AD-like CSF biomarker patterns. Mattsson et al., 2012 also
found increased sensitivity in MCI patients older tan 65 years com-
pared to MCI patients younger than 65 years. On the other hand,
Aβ42/p-tau specificity was not increased in any of the subgroups
meta-analyses except for young MCI patients (≤70 years), as dis-
cussed above. The three CSF biomarkers alone and the Aβ42/T-tau
ratio showed suboptimal predictive power except p-tau for MCI
cases converting to AD in ≤24 months, as already commented.
A better performance of the Aβ42/p-tau ratio over the other CSF
biomarkers has been reported in previous studies on MCI predic-
tion (Hansson et al., 2006; Mattsson et al., 2009; Buchhave et al.,
2012; Parnetti et al., 2012; Roe et al., 2013) and differential diag-
nosis between AD and other dementias (Maddalena et al., 2003;
Jong et al., 2006; Holtzman, 2011). This finding is likely due to this
ratio reflects two aspects of AD pathology, i.e., plaques (Aβ42), and
neurodegeneration (tau). Moreover, p-tau usually shows better
performance than T-tau (Mitchell, 2009; Bloudek et al., 2011; van
Harten et al., 2011), probably because p-tau is not only a marker
of axonal damage and neuronal degeneration, as T-tau, but it is
more closely related to AD pathophysiology and the formation
of neurofibrillary tangles (Anoop et al., 2010; Holtzman, 2011). In
addition, CSF p-tau concentrations in dementia with Lewy bodies,
frontotemporal lobar degeneration, and vascular dementia have
been referred to be more comparable to concentrations in con-
trols than to concentrations in AD patients (van Harten et al.,
2011). This positively affects prediction of MCI due to AD.
Regarding the clinical value of the CSF biomarkers, results for
negative likelihood ratios were normally better than results for
positive likelihood ratios. This means that the CSF biomarkers are
more useful to identify MCI patients that remain stable at follow-
up (MCI-S) than to rule-in MCI patients that will progress to AD
or dementia (MCI-C). This finding supports the consideration
made in the new MCI diagnostic criteria in relation to biomarkers
profile suggesting that the MCI syndrome is unlikely to be due
to AD (point 3.6.4. in Albert et al. (2011): “the definitive absence
of evidence of either Aβ deposition or neuronal injury strongly
suggests that the MCI syndrome is not due to AD”). Our study
shows that a normal result in the Aβ42/p-tau ratio has a moderate
decrease in the probability that the disease is present (conversion
to AD). This is true in all the situations evaluated in the differ-
ent subgroups meta-analyses, although we could not confirm this
for MCI cases converting to AD in ≤24 months because only one
study was available (Monge-Argilés et al., 2011). This single study
reported 86% sensitivity and 75% specificity (Monge-Argilés et al.,
2011). Therefore, it is quite probable that a meta-analysis of the
Aβ42/p-tau ratio in MCI cases converting to AD in ≤24 months
would provide a satisfactory negative likelihood ratio, given that
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both p-tau and the Aβ42/T-tau ratio showed optimal results. On
the other hand, positive likelihood ratios were normally within
the range of a small increase in the probability that the disease
is present. The only two situations where conclusive increase was
achieved are those already commented above (Aβ42/p-tau ratio
in young MCI patients and p-tau in MCI cases converting to
AD in ≤24 months). This finding may have implications for the
consideration made in the new MCI diagnostic criteria regarding
biomarkers pattern indicating a high likelihood that the MCI syn-
drome is due to AD [point 3.6.1. in Albert et al., 2011]. In particular,
young MCI patients with positive biomarkers of Aβ accumulation
and neuronal injury seems to have increased risk to decline or
progress to dementia due to AD in relatively short periods.
To determine in which specific situations the CSF biomarkers
provide satisfactory predictive performance is of great relevance.
In this study, some of those situations have been identified. How-
ever, despite these positive results, we acknowledge that much
additional work needs to be done to validate the application of the
CSF biomarkers as they are proposed in the new revised criteria
for MCI (Albert et al., 2011). The main limitation for extend-
ing the use of the CSF biomarkers to the clinical routine is the
difficulty to establish appropriate cut-offs. There is a big variabil-
ity in the cut-offs applied across the different studies. This is in
part related to differences in methodological aspects as well as
absence of technical standardization. In this meta-analysis, two
aspects related to variability in CSF methods were considered.
First, we tried to analyze the influence of different cut-offs for
the CSF biomarkers. Due to the great variability found it was not
possible to group the studies in order to perform specific sub-
groups meta-analyses (Table 1). Second, the technology for the
CSF analysis applied was also considered as potential confound-
ing factor. Results showed that sensitivity and specificity values
differed depending on whether xMAP (Luminex, Austin, US) or
ELISA (Innogenetics, Ghent, Belgium) technology was used. A
clear pattern was not found however. Therefore, future research is
mandatory to hopefully ascertain universal cut-offs values for the
CSF biomarkers. Several studies indicate that the standardization
of laboratory procedures could contribute to reduce variability in
the results (Hansson et al., 2006; Fagan et al., 2011; Mattsson et al.,
2011).
Therefore, standardization of methodological aspects is
expected to increase the clinical utility of the CSF biomarkers.
In this meta-analysis, we demonstrate that several confounding
factors are another source of variability in published diagnos-
tic/predictive performance and cut-offs. We show that CSF bio-
markers’ performance can be improved and heterogeneity reduced
by carefully considering these confounding factors. In this regard,
future studies should be addressed to explain how these factors
influence the diagnostic and predictive performance of the CSF
biomarkers. This need is reinforced by the fact that we could not
evaluate 13 of the 18 identified potentially confounding factors
given the lack of studies directly addressing these aspects. A related
limitation is the scarce number of studies available for some of the
analyses. This causes that certain subgroups meta-analyses could
be influenced by some of the other confounding factors. In order
to evaluate this, an analysis of coincident studies across factors
was performed. Table S5 in Supplementary Material shows that
most of the subgroups were rather independent from each other.
However, for p-tau and Aβ42/p-tau, studies including follow-up
periods >24 months coincided with studies with AD diagnosis
at follow-up; and for p-tau and Aβ42/T-tau, studies using xMAP
technology coincided with studies including MCI cases older than
70 years (and vice versa only for Aβ42/T-tau: ELISA technology
with studies including MCI cases younger than 70 years). Another
limitation is that systematic reviews and meta-analyses are essen-
tial tools for summarizing evidence accurately and reliably, but
might be susceptible of bias if not properly conducted. Following
PRISMA recommendations (Liberati et al., 2009; Moher et al.,
2010), several strategies were carefully considered in this study to
reduce risk of bias related to publication, data availability, and
reviewer selection. Evidence was rigorously reviewed and litera-
ture was supplemented with manual query of relevant studies in
order to minimize both publication and reviewer selection bias.
Selected studies were carefully examined for clues suggesting that
there may be missing results or data. Moreover, assessments were
completed independently by more than one reviewer and consen-
sus was required. Regarding the included studies, QUADAS-2 was
applied to evaluate risk of bias and results applicability. It must
be noticed that “domain 1” indicated high probability of patient
selection bias in six of the included studies, related to inclusion
of not completely consecutive or random samples, and not per-
fect avoidance of inappropriate exclusions. In particular, patients
were normally selected from specialized centers on the basis of
availability of CSF data, a procedure not generally performed in
all incoming patients. This fact, may have certain impact in the
applicability of the results, although these six studies scored rather
well in the other three domains, indicating that the index test, the
standard test, and flow and timing are not compromised. Another
drawback is that the follow-up period was used as rough mea-
sure of time to AD conversion. Therefore, although it is clear that
MCI-C cases in studies with follow-up ≤24 months converted to
AD in less than 24 months, it is possible that some MCI-C cases in
studies with follow-up >24 months also converted to AD before
the threshold of 24 months. Finally, sensitivity and specificity val-
ues above 80% were considered indicative of optimal predictive
performance according to international recommendations (The
Ronald and Nancy Reagan Research Institute of the Alzheimer’s
Association and the national Institute on Aging working Group,
1998). Higher levels are not easy to be achieved given that analy-
ses are derived from clinically diagnosed AD cases in which the
diagnostic accuracy already approximates 85% when validated
by the standard pathologic diagnosis at autopsy (Mendez et al.,
1992; Victoroff et al., 1995). None of the studies included in
this meta-analysis performed postmortem AD confirmation. It
is thus necessary to test CSF biomarkers’ predictive performance
in pathologically confirmed AD patients.
In conclusion, this study contributes to define several situa-
tions in which the CSF biomarkers seem to be clinically useful
for predicting conversion from MCI to AD. In particular, a base-
line CSF test result indicating Aβ42/p-tau pathological values in
MCI patients younger than 70 years has a moderate increase in the
likelihood of developing AD. Moreover, a baseline CSF test result
indicating pathological levels of p-tau increases the likelihood of
developing AD within the next 24 months. To move forward in
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the knowledge about how different confounding factors influence
the diagnostic and predictive performance of the CSF biomarkers
is of utmost importance. Such knowledge will help the elabora-
tion of a map of situations where the CSF biomarkers are useful,
so that clinicians and researchers know when the new diagnostic
criteria for MCI will be successful or otherwise prone to mistakes.
This will be crucial when new disease-modifying treatments are
available in the near future. Early prediction of MCI conversion
to AD is expected to maximize treatment benefit if applied to the
right people and before neuronal degeneration is too widespread
and patients are already demented. In addition, this has ethical
benefits because it is preferred not to treat patients with low risk
of AD in trials that could cause side effects. Finally, this will also
be important to enrich the samples with pure AD cases, both for
research and clinical trials.
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